Digest Network Come funziona
Network
/
Società
Vi
Non verificato

Vividion Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

13 comunicati stampa

Guarda tutti i comunicati
29/09/2026
Industria
Scienza
Libri/Editoria
Medicina - Varie
Comunicazione
Biotecnologia
Farmaceutica
Salute
Oncologia
Vividion Announces Publication of Clinical Data for VVD-214 in Nature Medicine, Highlighting Potential in Colorectal Cancer
Fonte
Vividion Therapeutics, Inc.
Emittente
Business Wire
1.00
0
23/06/2026
Eventi
Fiere
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Vividion Therapeutics Doses First Patient in Phase Ib Combination Study of WRN Inhibitor VVD-214 in Patients with Advanced Colorectal Cancer
Fonte
Vividion Therapeutics, Inc.
Emittente
Business Wire
1.00
0
06/01/2026
Oncologia
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Vividion Publishes Discovery of WRN Inhibitor VVD-214 in Journal of Medicinal Chemistry
Fonte
Vividion Therapeutics, Inc.
Emittente
Business Wire
1.00
0
22/12/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Industria
Vividion Publishes Discovery of First-in-Class KEAP1 Activator, Supporting Ongoing Clinical Program in Oncology
Fonte
Vividion Therapeutics, Inc.
Emittente
Business Wire
1.00
0
09/10/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Vividion Announces Publication in Science of Preclinical Data on Covalent Inhibitors of RAS-PI3K that Block Tumor Growth
Fonte
Vividion Therapeutics, Inc.
Emittente
Business Wire
1.00
0
13/08/2025
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Mercato del lavoro
Vividion Therapeutics Appoints Sam Whiting, M.D., Ph.D., as Chief Medical Officer
Fonte
Vividion Therapeutics, Inc.
Emittente
Business Wire
1.00
0
04/06/2025
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Vividion Therapeutics and Bayer Further Strengthen Oncology Development Pipeline with Clinical-Stage WRN Inhibitor
Fonte
Vividion Therapeutics, Inc.
Emittente
Business Wire
1.00
0
03/04/2025
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor for Treatment of Advanced Solid Tumors
Fonte
Vividion Therapeutics, Inc.
Emittente
Business Wire
1.00
0
22/01/2025
Mercato del lavoro
Biotecnologia
Farmaceutica
Salute
Oncologia
Vividion Therapeutics Announces Promotion of Jean Bemis to Chief Operating Officer
Fonte
Vividion Therapeutics, Inc.
Emittente
Business Wire
1.00
0
08/01/2025
Mercato azionario
Industria
Tecnica
Scienza
Biotecnologia
Software
Salute
Farmaceutica
Oncologia
Vividion Therapeutics Acquires Tavros Therapeutics to Expand Functional Genomics Capabilities and Boost Drug Discovery Platform
Fonte
Vividion Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0